China's Market Approval Policy and Medical Insurance Payment System for Rare Disease

Return to Insights Center

Related Insights

Blog

Unpacking NICE’s review of the HST routing criteria: implications for manufacturers

Oct 3, 2024

Blog

Accelerating Delivery and Patient Access to Rare Disease Treatments – Highlights from World Orphan Drug Congress

May 2, 2024

Podcast

Why Rare Disease Therapeutics Need Early Market Access Planning

Jan 4, 2023

Whitepaper

Overview of China's Market Approval Policy Med Insurance Payment System

Apr 7, 2022

Report

New Medicines, Novel Insights: Advancing rare disease drug development

May 22, 2023

Article

How biotechs can strengthen their value story with advanced analytics

Feb 15, 2022

Blog

Pragmatic Trials: Targeting evidence generation to inform market access and meet payers’ needs

Feb 8, 2022

Article

Three strategies for articulating a coherent product value story

Dec 18, 2021

Blog

Parexel names first Patient Ambassador

Jun 17, 2022

Article

EU Orphan Drug Designation – overcoming regulatory challenges

Jul 20, 2022

Report

New Medicines, Novel Insights: Accelerating development of cell and gene therapies

May 22, 2023

Blog

Rachel Smith joins Parexel as Executive Director and Head of the Rare Disease, Center of Excellence

Aug 10, 2022

Related Insights

Blog

Unpacking NICE’s review of the HST routing criteria: implications for manufacturers

Oct 3, 2024

Blog

Accelerating Delivery and Patient Access to Rare Disease Treatments – Highlights from World Orphan Drug Congress

May 2, 2024

Podcast

Why Rare Disease Therapeutics Need Early Market Access Planning

Jan 4, 2023

Whitepaper

Overview of China's Market Approval Policy Med Insurance Payment System

Apr 7, 2022

Report

New Medicines, Novel Insights: Advancing rare disease drug development

May 22, 2023

Article

How biotechs can strengthen their value story with advanced analytics

Feb 15, 2022

Show more